Company profile
HTG Molecular Diagnostics, Inc.
OTC: HTGMQ · Healthcare · Medical - Diagnostics & Research
#684 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 53GM —SS 35
v0.1 · 25/100 weight · pillars only
↑ growth stability, filing timeliness · ↓ market scale, return on equity
Methodology →Revenue TTM
$6.2M
Rev growth YoY (TTM)
-28.2%
Net income (FY)
-$21.6M
Employees
53
as of 2026-08-31
Market cap
$221
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.4M$6.4M2022
Net income-$21.6M-$21.6M2022
Operating income-$20.8M-$20.8M2022
Total assets$17.8M$17.8M2022
Liabilities$12.4M$12.4M2022
Equity$5.4M$5.4M2022
Revenue trend
FY2015 – FY2022 · USD
FY15
FY16
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is HTG Molecular Diagnostics, Inc.’s revenue?
HTG Molecular Diagnostics, Inc. booked $6.4M in FY2022 revenue, contracting 29% year over year — slower than 75% of Healthcare companies we track, at a -339.2% net margin.
Peers · Healthcare
Kyntra Bio, Inc.60CViveve Medical, Inc.——Korro Bio, Inc.41DJack Nathan Medical Corp.——Scorpius Holdings, Inc.——Decision Diagnostics Corp.——Neighbors
Pima →Key facts
CEOJohn L. Lubniewski
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersTucson, AZ
ExchangeOTC: HTGMQ
Employees53
IPO date2015-05-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.